Thalidomide: Difference between revisions

From The School of Biomedical Sciences Wiki
Jump to navigation Jump to search
Nnjm2 (talk | contribs)
No edit summary
mNo edit summary
Line 1: Line 1:
Thalidomide is a class of drugs used in the early 1960s as a sedative, as well as medication to alleviate morning sickness in pregnant woman. It was withdrawn from the UK market due to horrific side effects, whereby the offspring of the mother who had taken thalidomide were born with serious physical deformities, such as malformed or completely absent limbs and extremities.
Thalidomide&nbsp;(alpha-(N-phthalimido)glutarimide) is a synthetic glutamic acid derivative which was manufactured by the German pharmaceutical company Chemie Grunenthal in the 1950s<ref name="2">Bartlett, J.B., Dredge, K. and Dalgleish, A.G. (2004) ‘Timeline: The evolution of thalidomide and its IMiD derivatives as anticancer agents’, Nature Reviews Cancer, 4(4), pp. 314–322. doi: 10.1038/nrc1323.</ref>.&nbsp;&nbsp;The drug has sedative and antiemetic properties, making it a popular for combatting morning sickness in pregnant women. However, thalidomide was withdrawn from the market in early 1961, after clinicians William McBride<ref name="3">Mcbride, W.G. (1961) ‘THALIDOMIDE AND CONGENITAL ABNORMALITIES’, The Lancet, 278(7216), p. 1358. doi: 10.1016/s0140-6736(61)90927-8.</ref> and Widukind Lenz<ref>Lenz, W., Pfeiffer, R.A., Kosenow, W. and Hayman, D.J. (1962) ‘THALIDOMIDE AND CONGENITAL ABNORMALITIES’, The Lancet, 279(7219), pp. 45–46. doi: 10.1016/s0140-6736(62)92665-x.</ref> independently reported a link between the drug and birth defects. Thalidomide is a potent teratogen, causing dysmelia in humans<ref name="1">DʼAmatoRJ, Loughnan, M.S., Flynn, E. and Folkman, J. (1996) ‘Thalidomide is an inhibitor of Angiogenesis’, Retina, 16(3), p. 268. doi: 10.1097/00006982-199616030-00022.</ref>.&nbsp;


The deformities in the children were caused by the mixture of the L-form and D-form of the thalidomide molecule. The L-form was safe and worked effectively as a drug, but the D-form was harmful and caused the deformities. Due to modern technology, scientists have been able to isolate and distribute the safe form of thalidomide, and it is now&nbsp;prescribed as a&nbsp;form of cancer treatment.
The deformities in the children were caused by the mixture of the L-form and D-form of the thalidomide molecule. The L-form was safe and worked effectively as a drug, but the D-form was harmful and caused the deformities. Due to modern technology, scientists have been able to isolate and distribute the safe form of thalidomide, and it is now&nbsp;prescribed as a&nbsp;form of cancer treatment.  
 
 
 
 
 
=== References ===
 
<references />

Revision as of 17:15, 27 December 2016

Thalidomide (alpha-(N-phthalimido)glutarimide) is a synthetic glutamic acid derivative which was manufactured by the German pharmaceutical company Chemie Grunenthal in the 1950sCite error: Invalid <ref> tag; name cannot be a simple integer. Use a descriptive title.  The drug has sedative and antiemetic properties, making it a popular for combatting morning sickness in pregnant women. However, thalidomide was withdrawn from the market in early 1961, after clinicians William McBrideCite error: Invalid <ref> tag; name cannot be a simple integer. Use a descriptive title and Widukind Lenz[1] independently reported a link between the drug and birth defects. Thalidomide is a potent teratogen, causing dysmelia in humansCite error: Invalid <ref> tag; name cannot be a simple integer. Use a descriptive title

The deformities in the children were caused by the mixture of the L-form and D-form of the thalidomide molecule. The L-form was safe and worked effectively as a drug, but the D-form was harmful and caused the deformities. Due to modern technology, scientists have been able to isolate and distribute the safe form of thalidomide, and it is now prescribed as a form of cancer treatment.



References

  1. Lenz, W., Pfeiffer, R.A., Kosenow, W. and Hayman, D.J. (1962) ‘THALIDOMIDE AND CONGENITAL ABNORMALITIES’, The Lancet, 279(7219), pp. 45–46. doi: 10.1016/s0140-6736(62)92665-x.